Sun Pharma Secures Regulatory Approval to Manufacture and Sell Generic Wegovy in India

Sun Pharmaceutical Industries has received regulatory approval to manufacture and sell a generic version of the weight-loss drug Wegovy in India. The company will launch the drug under the brand name Noveltreat, once the semaglutide patent expires in March 2026. This is the second Indian drugmaker to receive approval for generic semaglutide, following Dr Reddy's Laboratories. The generic version is expected to enter the booming weight-loss market ahead of the patent expiry.